Pfizer, Inc. · NYSE:PFE
Pfizer — 29th Annual J.P. Morgan Healthcare Conference (January 2011)
21 slides from Pfizer's conference presentation, Jan 11, 2011
Slide 1: Delivering Scientific Advances That Impact Patients' Lives
Delivering Scientific Advances That Impact Patients’ Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements ● Our discussions during this presentation will include forward- looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2009 Annual R
Slide 3: Our Operating Model Drives Strong Alignment Between R&D and Business Units
Our Operating Model Drives Strong Alignment Between R&D and Business Units BioPharmaceutical Business Units Diversified Business Units Primary Specialty Established Emerging Animal Consumer Nutritional Oncology Capsugel Care Care Products Markets Health Health Health Pharma-Therapeutics Business Uni
Slide 4: Research and Business Units Utilize New Tools for Creating New Standards of Care
Together, the Research and Business Units Utilize New Tools Designed for Creating New Standards of Care What Differentiates ● Tools & Processes are the Asset? integrated to demonstrate (Medicine Differentiator Index) Commercial Why BUs should invest in Planned Viability this program? Label (Is the
Slide 5: Innovative Therapies in Key Areas of Unmet Medical Need
Innovative Therapies in Key Areas of Unmet Medical Need Neuroscience Pain/Inflammation Infectious Diseases Oncology Metabolic Disorders Our Focus is on High Priority Disease Areas Using Various Modalities Vaccines Small Molecules Biotherapeutics Working Together for a Healthier World™ 5
Slide 6: Pipeline Snapshot
Pipeline Snapshot* 25 Programs Advanced Discovery Projects Phase 1 Phase 2 Phase 3 In Reg. Total 46 37 26 9 118 31 projects discontinued since last update Pipeline Focused on Compounds in High-Priority Diseases * Pipeline snapshot as of Sept. 2010. Represents progress of R&D programs since 01/27/10;
Slide 7: Today's Late Stage Pfizer Portfolio
Today’s Late Stage Pfizer Portfolio In Registration Celebrex Chronic Pain Lyrica GAD (monotherapy) Xiapex Dupuytren's Contracture (MAA) Pristiq Vasomotor Symptoms of Menopause Viviant Osteoporosis Treatment and Prevention Tafamidis meglumine transthyretin amyloidosis polyneuropathy (MAA) Apixaban VT
Slide 8: Pfizer is a Leader in Specialty Care with a Strong Presence in Oncology
Pfizer is a leader in Specialty Care with a Strong Presence in Oncology Broad In-line Portfolio Infectious Diseases PVD / PAH * Endocrine Ophthalmics Specialty Care / Oncology Gastrointestinal BUs Neuroscience Disease Areas Di A Hemophilia Inflammation And Products 13 (pediatrics, Vaccines Musculosk
Slide 9: Select Late-Stage Candidates in Specialty Care & Oncology
Select Late-Stage Candidates in Specialty Care & Oncology Prevnar 13 for Adults (Vaccine) Pneumococcal Disease Tasocitinib (JAK inhibitor) Rheumatoid Arthritis Crizotinib (ALK inhibition) Non-Small Cell Lung Cancer Axitinib (VEGF inhibition) Metastatic Renal Cell Cancer Working Together for
Slide 10: Prevnar Adult: An Important Healthcare Opportunity
Prevnar 13 Adult: An Important Healthcare Opportunity High Significant Excellent Incidence Unmet Need Profile IPD incidence in adults IPD and Pneumococcal Building on the >50 is similar to the Pneumonia are scientific foundation of incidence in children <51 associated with Prevnar mortality and sign
Slide 11: Prevenar 13 Adult efficacy trial
Prevenar 13 Adult ● Placebo-controlled efficacy trial of vaccine-type community acquired pneumonia in adults >65 years ● Conducted in the Netherlands ● 84,000+ subjects enrolled, largest study of its kind Working Together for a Healthier World™ 11
Slide 12: Tasocitinib Studied in a Wide Range of RA Patient Populations in ORAL Trials
Tasocitinib (CP-690,550) is being Studied in a Wide Range of RA Patient Populations in the ORAL Trials Program The Phase 3 program consists of six studies at more than 350 locations in 35 countries worldwide evaluating patients with active RA More than 5000 people have taken tasocitinib in clini
Slide 13: Tasocitinib (CP-690,550): A Novel, Oral Rheumatoid Arthritis Agent
Tasocitinib (CP-690,550): A Novel, Oral Rheumatoid Arthritis Agent CP-690,550 CP- Pfizer arthritis drug succeeds in late stage trial (Inflammation) --- - Meets goal on two of three primary endpoints - - Significantly improves symptoms, physical function - Novel MOA inhibiting - Serious adverse event
Slide 14: CP-690,550 Evaluated in Other Inflammatory and Immunologic Diseases
CP-690,550 is Being Evaluated in a Number of Other Inflammatory and Immunologic Diseases Phase of Disease Prevalence* Current Market* Projected Market *(2019) Development (2011) (2011) (CAGR; 2011-2019) Rheumatoid Arthritis III 5.3M $9.0B $12.5B (4%) Psoriasis III 14.3M $3.3B $4.8B (5%) Psoriatic II
Slide 15: One of the Strongest Phase III Oncology Pipelines in the Industry
Pfizer has one of the strongest Phase III Oncology Pipelines in the Industry with a range of approaches to treating cancer Adhesion Angiogenesis ALK-1 mAb Cell Cycle & (PF-03446962) Metabolism Α5/β1 mAb Immunotherapy (PF-04605412) Signal PI3K/mTor-PO Transduction Sunitinib (PF-04691502) (SU-011248)
Slide 16: Oncology Focus on Personalized Medicine
Oncology Focus on Personalized Medicine Benefit to Clinical Development Benefits of Approach # Patients Leverage patient selection 800 strategies to reduce 400 study size: – Less expensive Bigger Treatment Effect 18 Months 30 – Faster completion Achieve h earlier l regulatory l submission and la
Slide 17: Crizotinib: Potential Breakthrough in Personalized Medicine For Lung Cancer Patients
Crizotinib: Potential Breakthrough in Personalized Medicine For Lung Cancer Patients Working Together for a Healthier World™ 17
Slide 18: Crizotinib's Rapid Timeline from Research to Development
Crizotinib’s Rapid Timeline from Research to Development First clinical Lead Discovery of responses Phase 3 lung Abstract selected Compound Clinical Testing EML4-ALK cancer trial for plenary session Begins observed; tumors + Identified T Translocation l ti f EML4-ALK for EML4 ALK initiated at ASCO 2
Slide 19: Axitinib: Strong Efficacy Data Shows Potential for Differentiation
Axitinib: Strong Efficacy Data Shows Potential for Differentiation – Key Asset in 1st in Class RCC Franchise Global RCC Targeted Therapy Sales Pfizer Announces Positive Phase 3 Trial $2,500 $2,348 MM Results For Axitinib In Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC) $2,0
Slide 20: Pfizer's Structure Enhances Our Focus and Expertise
Pfizer’s Structure Enhances Our Focus and Expertise Running Our Diverse Businesses New Tools & Processes for Enhanced Decision- Decision- Making g and Accountability y for Development p of Meaningful Medicines Rich Pipeline with Several Assets in Registration and Late Stage Development Working Toget
Slide 21: Delivering Scientific Advances That Impact Patients' Lives
Delivering Scientific Advances That Impact Patients’ Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011
Pfizer — 29th Annual J.P. Morgan Healthcare Conference (January 2011) on 6ix